Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs

Preston Klassen, Cavalry Biosciences CEO June 8, 2026 09:52 AM EDT FinancingStartups Cav­al­ry Bio­sciences pur­sues $75M Se­ries B to test eye and mus­cle dis­or­der drugs Kyle LaHucik Biotech Correspondent Cav­al­ry Bio­sciences, the first biotech out of in­cu­ba­tor and in­vestor Jupiter Bioven­tures, is work­ing on a $75 mil­lion Se­ries B to bring its first two … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER